Reports over the past few days reported that that Mellanox is looking at a potential has quickly driven up the price of its stock.
ReWalk Announces Launch of 522 Post-Market Study with Stanford University School of Medicine as Lead Investigator Site
The 522 study will follow 60 patients for one year, and will include as many as 15 centers across the United States.